title: Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth.
abstract: The Ewing family of tumors is a group of highly malignant tumors that mainly arise in bone and most often affect children and young adults in the first two decades of life. Despite the use of multimodal therapy, the long-term disease-free survival rate of patients with Ewing tumors is still disappointingly low, making the discovery of innovative therapeutic strategies all the more necessary. We have recently shown that cholecystokinin (CCK), a neuroendocrine peptide, involved in many biological functions, including cell growth and proliferation, is a relevant target of the EWS/FLI1 oncoprotein characteristic of Ewing tumors. CCK silencing inhibits cell proliferation and tumor growth in vivo, suggesting that CCK acts as an autocrine growth factor for Ewing cells. Here, we analyzed the impact of two CCK receptor antagonists, devazepide (a CCK1-R antagonist) and L365 260 (a CCK2-R antagonist), on the growth of Ewing tumor cells. Devazepide (10 micromol/l) inhibited cell growth of four different Ewing tumor cells in vitro (range 85-88%), whereas the effect of the CCK2-R antagonist on cell growth was negligible. In a mouse tumor xenograft model, devazepide reduced tumor growth by 40%. Flow cytometry experiments showed that devazepide, but not L365 260, induced apoptosis of Ewing tumor cells. In summary, devazepide induces cell death of Ewing tumor cells, suggesting that it could represent a new therapeutic approach in the management of Ewing's tumor patients.
authors.affiliation: Laboratorio de Genética y Patología Molecular de Tumores Sólidos Infantiles, Departamento de Biología Molecular y Celular del Cáncer, Instituto de Investigaciones Biomédicas A. Sols (CSIC-UAM), Madrid 28029, Spain.
authors.forename: Jaime
authors.initials: J
authors.lastname: Carrillo
authors.forename: Noelia
authors.initials: N
authors.lastname: Agra
authors.forename: Noemí
authors.initials: N
authors.lastname: Fernández
authors.forename: Angel
authors.initials: A
authors.lastname: Pestaña
authors.forename: Javier
authors.initials: J
authors.lastname: Alonso
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001570:Benzodiazepinones / Q000494:pharmacology; D045744:Cell Line, Tumor; D020109:Devazepide / Q000494:pharmacology*; D005260:Female; D005434:Flow Cytometry; D006727:Hormone Antagonists / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010671:Phenylurea Compounds / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000503:physiopathology; D023041:Xenograft Model Antitumor Assays
chemical_list: D001570:Benzodiazepinones; D006727:Hormone Antagonists; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; C058121:L 365260; D020109:Devazepide